CSF3 and graft versus host disease: Findings presented here and in previous publications evaluating BEN in haplo-BMT (12, 13, 15–19, 55, 63) may be applicable to other types of allo-HCT, such as unrelated HLA-matched or mismatched HCT, G-CSF mobilized peripheral blood stem cell grafts, or others, and supports the notion of further evaluating BEN as a GvHD prophylaxis therapy.